Advances in Cancer Immunotherapy
Thu, Oct 10
|Courtyard by Marriott Boston Downtown
Thursday, Oct. 10, 2019 3:30 p.m. EDT Organizers: Elizabeth Buchbinder, MD – Dana-Farber Cancer Institute David F. McDermott, MD – Beth Israel Deaconess Medical Center Virginia Seery, MSN, RN, ANP-BC – Beth Israel Deaconess Medical Center
Time & Location
Oct 10, 2019, 3:30 PM – 8:00 PM
Courtyard by Marriott Boston Downtown, 275 Tremont St, Boston, MA 02116, USA
Guests
About The Event
The Society for Immunotherapy of Cancer (SITC) is the world’s leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy.
Each year SITC offers a series of free regional Advances in Cancer Immunotherapy™ (ACI) programs – with one coming to Boston in October.
These programs, developed by a team of providers, are CME-, CNE-, CPE- and MOC-accredited, presented by local authorities in tumor immunology and cancer immunotherapy and are FREE for healthcare professionals in the clinical setting, students and patient advocates.
ACI Program - Boston
Thursday, Oct. 10, 2019
3:30 – 8:20 p.m. EDT
Courtyard Boston Downtown 275 Tremont Street; Boston, MA 02116
Attendees will leave this program with the ability to:
- Treat patients with FDA-approved immunotherapies
- Interpret new clinical data supporting the use of checkpoint inhibitors, CAR T therapies, cytokines, oncolytic viruses and vaccines
- Identify and manage irAEs
- Employ strategies to overcome operational and reimbursement barriers to incorporating immunotherapy into your practice
- Apply foundational knowledge for clinical implementation of SITC's Cancer Immunotherapy Guidelines
- Anticipate forthcoming immunotherapy trends/treatments/trials and how they impact your patients and practices
- Recognize common and uncommon toxicities in immunotherapy patients and provide solutions/adjustments in treatment to address them